Nutrition and exercise during hospital induction for adults with Philadelphia chromosome–negative B‑ALL
Official title: Nutrition and Exercise to Optimize Muscle and Adiposity in Adults With ALL: NEOMA ALL Trial
Run by University of Chicago · NCT06785324 · Data updated 2026-11-12
This program will test whether guided nutrition and in-hospital exercise during induction therapy help adults with Philadelphia chromosome–negative B‑ALL keep muscle and limit excess body fat.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 50 Years |
| Sex | All |
| Enrollment | 20 (estimated) |
| Sponsor | University of Chicago Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Chicago, Illinois) |
| Status | Recruiting |
| Started | May 12, 2025 |
| Main results expected | November 6, 2027 |
| Study ends | November 6, 2027 |
| Registry record updated | June 19, 2025 |
| Trial ID | NCT06785324 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults with a new diagnosis of Philadelphia chromosome–negative B‑ALL who are receiving inpatient, pediatric‑inspired induction chemotherapy, have BMI >18.5, and are able to follow the diet and exercise plans.
✕Probably not a fit
Patients who are underweight (BMI ≤18.5), cannot follow the diet or exercise program, are pregnant, or have medical limitations preventing participation are unlikely to benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This interventional program enrolls adults newly diagnosed with Philadelphia chromosome–negative B‑cell ALL who are hospitalized for intensive pediatric‑inspired induction chemotherapy. Participants receive a tailored nutrition plan and a supervised in-hospital physical exercise intervention while wearing a Fitbit to record activity. Muscle mass and measures of adiposity will be tracked to see whether the combined interventions better preserve lean tissue and limit fat gain during induction. Patients with BMI ≤18.5, those unable to follow the regimens, or who are pregnant are excluded.
Why it matters
Potential benefit: If successful, the interventions could help patients preserve muscle, limit excess fat, and improve physical resilience during and after induction therapy.
How similar studies have gone: Exercise and nutrition interventions have been shown to preserve muscle and improve outcomes in other cancer populations, but using this combined inpatient approach in adults with Ph‑negative B‑ALL is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * New Diagnosis of Philadelphia Chromosome Negative B-ALL * Receiving intensive pediatric-inspired induction chemotherapy Exclusion Criteria: * BMI ≤18.5 kg/m2 at time of diagnosis * Unable to comply with both the recommended diet and exercise regimen as deemed by the research or treatment team * Pregnant
Where it's running
-
University of Chicago Medicine Comprehensive Cancer Center
Chicago, Illinois, United States Recruiting
Study contacts
- Principal investigator: Wendy Stock — University of Chicago
- Study coordinator: Clinical Trials Intake
- Email: cancerclinicaltrials@bsd.uchicago.edu
- Phone: 1-855-702-8222
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
TSLPR-CART therapy for CRLF2-R/TSLPR–expressing B-ALL in adults
This study tests a CAR T-cell treatment called TSLPR-CART in adults whose B-ALL cells overexpress TSLPR and have not responded to standard therapy.
-
CD19 CAR-T versus donor lymphocyte infusion for clearing MRD after allogeneic stem cell transplant in Ph-negative B-ALL
This trial tests whether a single infusion of autologous CD19 CAR-T cells or chemotherapy plus donor lymphocyte infusion better clears minimal residual disease in patients aged 3–79 with Ph-negative B‑cell ALL after allogeneic stem cell transplant.
-
Vaccine protection after blinatumomab in children with B-ALL
This project will see if children and young adults (ages 1–21) with B-cell acute lymphoblastic leukemia who received blinatumomab keep protective immunity from routine childhood vaccines and whether revaccination restores immunity when levels are low.
-
Using CD22 CAR T-cells to extend remission after commercial CD19 CAR T-cell therapy in children, adolescents, and adults with relapsed/refractory B‑ALL
This will try giving CD22-targeted CAR T-cells to people aged 3–65 who are in remission after CD19 CAR T-cell therapy to see if it helps keep their B-ALL from coming back longer.
-
KSV01 injection for adults with relapsed or refractory B‑cell acute lymphoblastic leukemia
This will test a new KSV01 CAR therapy injection to see if it is safe and helps adults with relapsed or refractory B‑cell acute lymphoblastic leukemia.
-
Senl_B19 (S1904) CD19 CAR-T for relapsed or refractory CD19+ B-ALL in children and young adults
This trial will test S1904 (Senl_B19) CD19 CAR-T cells in children and young adults aged 3–25 with relapsed or refractory CD19-positive B-cell acute lymphoblastic leukemia.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.